Kornimate/medical-research-clean huggingface dataset:
peripheral magnetic stimulation to treat patient with post-stroke shoulder-hand syndrome

Conditions: Reflex Sympathetic Dystrophy of Upper Limb; Stroke

Summary: shoulder-hand syndrome is a common complication following stroke, constituting of excessive pain, swelling, heat, limited range of motion, and trophic change of the affected limbs. it not only has an extensive negative impact on both physical and psychological aspects of a stroke patient's well-being, but also impose burden on the health care system and the patient's family. despite its relatively high incidence, there is neither well-established treatment protocol, nor high quality evidence for a single effective treatment. the objective of the present study is to investigate the efficacy, including pain, spasticity, and subluxation reduction, muscle strengthening, and shoulder range of motion improvement, of high-intensity peripheral magnetic stimulation generated by the super-inductive system to treat patients with post-stroke shoulder-hand syndrome.

the present study aims to investigate the therapeutic effects achieved by the peripheral magnetic stimulation for treating post-stroke shoulder-hand syndrome. the investigators plan to use high-intensity peripheral magnetic stimulation generated by the super-inductive system for treatment of post-stroke shoulder-hand syndrome. in terms of study design, the treatment group will receive 10 sessions of high-intensity peripheral magnetic stimulation 5 days a week for 2 weeks, with physical and occupational therapy kept as usual; while the control group will only receive conventional physical and occupational therapy. comprehensive assessment, including history taking and physical examination testing for muscle strength, spasticity, shoulder range of motion, before and after the intervention will be conducted for evaluation.

Eligibility criteria:
inclusion criteria: * \>=20 years old * stroke in recent 6 months * clear consciousness * clinical diagnosis of post-stroke shoulder-hand syndrome exclusion criteria: * acute bursitis, tendonitis or tendon tear * fracture, dislocation or joint infection within 3 months * malignancy at treatment site * seizure * prosthesis or implant at treatment site * pregnancy

Keywords: shoulder pain magnetic stimulation electric stimulation reflex sympathetic dystrophy
peng with lfcb vs. esp blocks for pediatric hip surgery

Conditions: Hip Disease; Hip Dysplasia; Hip Arthropathy

Summary: this randomized controlled trial (rct) compares the analgesic effectiveness of two regional anesthesia techniques-pericapsular nerve group (peng) block combined with lateral femoral cutaneous nerve block (lfcb) versus lumbar and sacral erector spinae plane blocks (l-espb and s-espb)-in pediatric patients undergoing hip surgery.

orthopedic hip procedures in pediatric patients, including osteotomies, arthroscopic interventions, and reconstructive surgeries, often result in significant postoperative pain. effective analgesia is critical for reducing surgical stress, accelerating rehabilitation, and minimizing opioid use and associated side effects. regional anesthesia techniques have gained attention for their opioid-sparing effects and enhanced recovery profiles. this randomized controlled trial aims to compare the analgesic effectiveness of two regional anesthetic approaches: - the pericapsular nerve group (peng) block is combined with the lateral fetal cutaneous nerve block (lfcb), targeting hip joint innervation directly and providing comprehensive sensory coverage. lumbar and sacral erector spinae plane blocks (l-espb and s-espb) employ fascial plane techniques to deliver analgesia by diffusing local anesthetic around nerves innervating the hip region. this trial aims to establish the optimal regional anesthesia technique and determine the clinical benefits of using dexamethasone and dexmedetomidine as adjuvants. the results will guide clinicians toward evidence-based analgesic protocols in pediatric orthopedic hip surgery, potentially reducing opioid-related complications and improving patient recovery outcomes.

Eligibility criteria:
inclusion criteria: * pediatric patients aged between 2 and 16 years. * scheduled for elective orthopedic hip surgery, including: osteotomies and hip reconstruction surgeries * asa (american society of anesthesiologists) physical status classification: i-iii. * written informed consent obtained from the patient's legal guardian(s). exclusion criteria: * known allergy or hypersensitivity to any of the study medications * presence of infection or inflammation at the intended injection site(s) of regional anesthesia. * coagulopathy or bleeding disorders (including patients on anticoagulant therapy) that contraindicate nerve blocks. * neurological disorders or peripheral neuropathies that could influence sensory or motor assessment of the lower limbs. * cognitive impairment or behavioral disorders significantly affecting pain assessment accuracy or cooperation. * history of chronic opioid use or known substance abuse. * severe systemic disease or condition compromising patient safety or interfering with study protocol adherence.
a study to prevent and improve sexual health concerns for people with breast cancer

Conditions: Improve Sexual Health; Improve Vulvovaginal Health

Summary: researchers are doing this study to look at whether sexual health counselling and using non-hormonal moisturizer at the start of ovarian suppression may be able to prevent or reduce side effects such as vaginal dryness and sexual dysfunction. researchers will compare how effective this prevention intervention works compared to the usual approach, which is to treat these side effects after they start. all participants will also complete surveys about their sexual health. this information will help researchers learn more about the sexual health of women with breast cancer receiving ovarian suppression.

50 premenopausal or perimenopausal women who are receiving ovarian suppression as part of their breast cancer treatment will be randomized to upfront intervention vs at the time of symptom development (standard of care). patients will have subjective and objective monitoring of vaginal dryness and sexual dysfunction.

Eligibility criteria:
inclusion criteria: * women, 18 years of age or older * breast cancer patients with hormone receptor positive breast cancer , stage 0-iii * premenopausal or perimenopausal women who have either been pregnant or had at least one menstrual period in the last 24 months or have/had an iud in place * patients currently on or are being initiated on ovarian suppression * patients are asymptomatic for vaginal symptoms of estrogen deprivation (i.e. vaginal dryness, dyspareunia, or discomfort \[pain with intercourse or examination\]) and score a 3 or less on the vas and vuas exclusion criteria: * postmenopausal women who have been without a period for ≥ 2 years * patients who score a 4 or above on the vas and vuas * patients already using vva treatment (e.g. intravaginal estrogen, other non-hormonal moisturizer or suppository), unless discontinued with washout of 4 weeks

Keywords: sexual health concerns prevention premenopausal female breast cancer patients receiving ovarian suppression 23-109
deep brain stimulation for treatment refractory ptsd

Conditions: Post-Traumatic Stress Disorder

Summary: this is a phase i, non-blinded, non-randomized, pilot trial for safety and efficacy of deep brain stimulation for ptsd. a substantial number of individuals continue to experience ptsd symptoms despite appropriate medical treatment. in psychotherapy-based studies, over 30% of patients that completed a full course of treatment continue to meet criteria for ptsd. response rates to treatment with ssris are usually no higher than 60%. this study would be the first exploration of a surgical therapy for refractory ptsd. the subgenual cingulate plays a role in mechanisms of this disorders and has been successfully targeted with dbs for the treatment of depression. the development of a therapy that targets brain structures known to play a role in this disease would be a substantial step forward in the treatment and understanding of these conditions.


Eligibility criteria:
inclusion criteria: 1. female or male patients between age 18-70 2. diagnosis of posttraumatic stress disorder as defined by the diagnostic and statistical manual fifth edition (dsm v). 3. treatment resistance as defined by the persistence of clinical symptoms despite adequate treatment with four modalities, including a) selective serotonin reuptake inhibitors, b) cognitive behavioral therapy, c) other classes of medications and/or psychotherapy. 4. severe forms of the disease as measured by clinician administered ptsd scale (caps) scores ≥ 50. 5. a pattern of chronic stable ptsd lasting at least 1 year. 6. ability to provide informed consent and comply with all testing, follow-ups and study appointments and protocols exclusion criteria: 1. any past or current evidence of psychosis or mania (patients with co-morbid depression will not be excluded from the study) 2. active neurologic disease, such as epilepsy 3. alcohol or substance dependence or abuse in the last 6 months, excluding caffeine and nicotine 4. current suicidal ideation 5. any contraindication to mri or pet scanning 6. likely to relocate or move out of the country during the study's one year duration 7. presence of clinical and/or neurological conditions that may significantly increase the risk of the surgical procedure. 8. currently pregnant (as determined by history and serum hcg) or lactating; for females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation
ultrasonic scaler vs erythritol for peri-implant maintenance of loaded implants with crowns made by different materials

Conditions: Peri-implant Mucositis

Summary: the aim of the study is to assess the effect of a 12-month peri-implant protocol with erythritol orultrasonic scaler with peek inserts for dental implants with crowns made by different materials . patients will be randomly divided into two groups: erythritol group: erythritol with a particle size of \~14 µm will be used for 5 seconds (airflow® plus ems) ultrasonic scaler group: a piezoelectric handpiece with peek inserts (mini piezon ems; pi ems) . different subgroups will be defined according to the material of the dental crown of the related implant. the mechanical debridement appointments will be carried out at the baseline, after 6 months, and after 12 months, after instruction and motivation of the patient, completion of the clinical chart with the recording of the probing depth (evaluation in mm of the peri-implant sulcus taken by a periodontal probe; 4 surfaces of the gingival margin are detected: vestibular, palatal/lingual, mesial, distal), bleeding on probing and plaque control record.


Eligibility criteria:
inclusion criteria: * age between 18 and 70 * presence of at least one dental implant * good compliance exclusion criteria: * patients with cardiac stimulators * patients with neurological disorders * patients with psychological disorders * pregnant women
the use of abdominal binders in patients undergoing cesarean sections

Conditions: Cesarean Section Post Operative Management

Summary: to see if the use of abdominal binders improves patients out comes after cesarean delivery

inclusion: all patients admitted to labor and delivery consented patients who had a cesarean delivery will be randomized using a number table to receive or not receive an abdominal binder. outcomes: on postoperative days 1 and 2, patients were asked to complete a pain visual analog scale and the validated symptom distress scale. postoperative hemoglobin and hematocrit were also recorded.

Eligibility criteria:
inclusion criteria: women undergoing cesarean section for any indication exclusion criteria: * unable to give consent

Keywords: cesarean section postoperative pain pregnancy abdominal binder
a prospective, multicenter, blind, randomized controlled, optimal clinical trial to evaluate the safety and efficacy of medical collagen fillers for facial dermal tissue filling to correct frontal wrinkles (crow's feet)

Conditions: Intentional Correction of Forehead Wrinkles (crow&#39;s Feet)

Summary: with the development of medical technology and the improvement of life treatment, people's concept of aging is also changing, people of all ages are constantly pursuing a young and healthy life, the use of lasers and fillers to correct facial wrinkles has become more and more common. for the use of fillers to correct facial wrinkles, the efficacy and safety have been fully established, to the extent that it is a minimally invasive treatment, due to its short operation time and rapid recovery, it is considered a very effective treatment for facial wrinkles. collagen is a kind of natural protein. as the main component of skin tissue, it has the advantages of good biocompatibility, degradability and low immunogenicity, and is an ideal material for correcting facial soft tissue defects. collagen is implanted under the skin in a non-surgical way to increase the capacity of the dermis tissue, thus achieving the purpose of smoothing wrinkles, improving facial defects, and sculpting perfect skin. the medical collagen filling agent of filaman (changchun) pharmaceutical biotechnology co., ltd. consists of 3.5% bovine collagen it is composed of 0.3% lidocaine hydrochloride saline suspension, and is filled by injection to repair the shape and correct the contour to achieve satisfactory results. the product is eventually completely degraded in the human body, and the expected absorption time is 6-12 months. in accordance with the requirements of the medical device registration and filing management measures, the medical device clinical trial quality management standards, the clinical trial registration review guidelines for facial injection fillers (draft for comment), the clinical trial design guidelines for medical devices, and the ethical principles of the declaration of helsinki of the world medical congress, to maximize the benefit of the subject and avoid as much harm as possible.


Eligibility criteria:
inclusion criteria: * age 18-65 years old (including 18 and 65 years old), regardless of gender; intentional correction of forehead wrinkles (crow's feet); exclusion criteria: * received bovine collagen fillers or hyaluronic acid within 12 months prior to enrollment facial area of calcium hydroxyapatite (caha), poly-l-lactic acid (plla) or plastic therapy domain therapy, or subjects who plan to receive such therapy during study participation;
assesment of tdapp1 an ehelath tool to make therapeutic recommendations for patients with adhd

Conditions: Attention Deficit-hyperactivity Disorder

Summary: this is a 3-week open label, one group study to determine the agreement between the pharmacological treatment recommended by tdapp1 and the interventions recommended by relevant clinical practice guidelines.

clinical practice guidelines (cpgp) allow optimizing medical decisions and health care based on the best evidence available. nevertheless, cpgs have several limitations. first, many gpc are outdated shortly after their publication. second, cpg recommendations are often not applicable to many patients treated in clinical practice. most cpgs do not make recommendations for patients with a mild disorder or for complex patients with comorbiditie. another limitation is that patients involvement in cpgs development is still poor. we aim to develop and assess tdapp1: an ehealth tool to formulate participatory, individualized and automated therapeutic recommendations for patients with attention deficit hyperactivity disorder. a 3-week, one group, open label study will be conducted. fifty-five patients aged 6-65 with adhd will use tdapp1. the therapeutic recommendations made by the tdapp1 and by relevant cpg will be compared. concordance in the recommendations will be studied. effectiveness, safety, changes in physical activity and satisfaction will be investigated.

Eligibility criteria:
inclusion criteria: * male and female patients ages 6-65 * a diagnosis of dsm-v adhd based on clinical assessment exclusion criteria: * patients under adequate therapeutic treatment or requiring minor adjustments * patients lacking an electronic device (mobile phone, tablet,...) with internet access

Keywords: ehealth evidence based medicine machine learning
a study of bnc210 in elderly patients with agitation

Conditions: Agitation in the Elderly

Summary: this is a phase ii randomised, double-blind, placebo-controlled study assessing the effects of bnc210 on agitation in hospitalised elderly patients as measured by the pittsburgh agitation scale (pas). safety and tolerability of bnc210 will also be assessed. the secondary objectives of the study include evaluation of the effects of bnc210 on global function in patients with agitation as assessed by the clinical global impression scale (cgi-s/i). participants will receive 5 days of blinded treatment followed by 2 days of follow up.


Eligibility criteria:
key inclusion criteria: * male or female elderly patient admitted to hospital and under the care of a specialist geriatrician * determined to have agitation requiring intervention in addition to standard of care behavioural management, as assessed by the investigator or delegate, after at least 24 hours following admission to hospital. key exclusion criteria: * severe alzheimer's dementia (stage 7) as assessed by the functional assessment staging test (fast). * diagnosed with severe parkinson's disease. * premorbid psychotic illness as assessed by the investigator. * evidence of severe organ dysfunction * confirmed metastatic malignancy.
serum anti-mullerian hormone (amh) levels in overweight and obese adolescent girls with polycystic ovaries

Conditions: Polycystic Ovary Syndrome

Summary: in this study the investigators aimed to investigate whether there is a relation between body weight and serum anti mullerian hormone levels in adults with polycystic ovary syndrome. for this purpose the investigators designed a prospective study including three groups. the group i is defined as adults with polycystic ovary syndrome and body mass index is greater than 25. the group ii is defined as adults with polycystic ovary syndrome and body mass index is less than 25. the group iii is defined as adults with non-polycystic ovary syndrome and body mass index is less than 25. the all three groups are compared considering their serum amh levels,lipid profiles, sex steroids and glycemic analyses.

in this study the investigators aimed to investigate whether there is a relation between body weight and serum anti mullerian hormone levels in adults with polycystic ovary syndrome. for this purpose the investigators designed a prospective study including three groups. the diagnosis of polycystic ovary syndrome was made in the presence of ;oligo- and/or anovulation,clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries. clinical hyperandrogenism was defined by the presence of hirsutism , acne, or the presence of androgenic alopecia , biochemical hyperandrogenemia was defined as a serum level of total testosterone higher than 2.60 nmol/l, body mass index (bmi) was calculated as weight in kilograms divided by the square of height in meters. the patients were classified as obese with bmi ≥ 25 kg/m2 , adolescent patients were diagnosed 2 years after menarche in order to avoid the misdiagnosis of transitory functional hyperandrogenism and menstrual disorders during puberty. the all three groups are compared considering their serum amh levels,lipid profiles, sex steroids and glycemic analyses.

Eligibility criteria:
inclusion criteria: the participants with the following findings;oligo- and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries, presence in each ovary of 12 or more follicles measuring 2-9 mm in diameter and/or increased ovarian volume (\> 10 ml). exclusion criteria: the participants with the following findings;pregnancy,breastfeeding,known liver disease or alanine aminotransferase (60 iu/l), creatinine (130 mmol/l), known alcohol abuse, diabetes mellitus and treatment with oral glucocorticoids or hormonal contraceptives. patients could be included if hormonal contraception had been discontinued at least 1 month previously.

Keywords: polycystic ovary syndrome anti-mullerian hormone obesity
physiotherapy-led outpatient clinic for patients with spondyloarthritis

Conditions: Spondylarthritis; Spondylitis, Ankylosing; Spondylarthropathies; Sacroiliitis; Arthritis, Psoriatic

Summary: the purpose of this study is to determine whether patients with spondyloarthritis are more satisfied with a physiotherapy-led outpatient clinic than usual care and whether there is a difference between patients in a physiotherapy-led outpatient clinic and those in usual care regarding disease activity, function and mobility.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis spondyloarthritis, ankylosing spondylitis, spondylarthropathy, juvenile ankylosing spondylitis, psoriatic arthritis with affection of the spine * age between 18 and 45 (born 1969 - 1996) exclusion criteria: * also diagnosed with potentially functionally impairing neuromuscular, neurological or muscular disorders * insufficient norwegian language skills * cognitive impairment * no sign of inflammation or bone erosions in the sacroiliac joints or in the spine on imaging

Keywords: physiotherapy outpatient clinic
long-term open-label safety and efficacy study of adalimumab in subjects with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: to assess the long-term safety and maintenance of response of adalimumab in subjects with ulcerative colitis who participated in and successfully completed m06-826 (nct00385736) or m06-827 (nct00408629).


Eligibility criteria:
inclusion criteria: * subject must have successfully enrolled and completed either study m06-826 (nct00385736) or study m06-827 (nct00408629) * subject is judged to be in generally good health as determined by the principal investigator exclusion criteria: * subject has not responded to weekly adalimumab therapy in m06-826 (nct00385736) or m06-827 (nct00408629) * subject considered by the investigator, for any reason, to be an unsuitable candidate * female subject who is pregnant or breast-feeding or considering becoming pregnant

Keywords: ulcerative colitis